The present study assessed the effect of Ruscus aculeatus-hesperidin-methyl-chalcone-ascorbic acid (HMC-AA) on the quality of life (QoL) of patients suffering from chronic venous disorders (CVDs).
An observational, multicentre and prospective study was performed with 917 Mexican patients suffering from CVD. Patients were treated with R. aculeatus-HMC-AA. After 12 weeks of treatment, the physicians then assessed the patients' symptoms and QoL using Short Form (SF-12) and Chronic Venous Insufficiency (CIVIQ) auto-questionnaires.
Patients were mainly women (86.7%), overweight or obese (72.7%) or C2 (39.3%)-C3 (27.6%). All symptoms and ankle circumferences significantly improved over time, with increasing clinical, aetiological, anatomical and pathophysiological (CEAP) classes and body mass index (BMI) (P < 0.001). Concerning QoL, all dimensions of the SF-12 score significantly improved over time (P < 0.001). Moreover, the CIVIQ scores significantly improved (P < 0.001) with increasing BMI (P < 0.002) and CEAP classes (P < 0.05).
R. aculeatus-HMC-AA significantly improved the symptoms and QoL of CVD patients.
[Show abstract][Hide abstract] ABSTRACT: In this paper we are concerned with the exponential risk-sensitive
version of the standard average cost criterion for controlled Markov
chains (CMC). Our presentation is mathematically rigorous, and our proof
techniques are self-contained and perhaps somewhat intuitive.
Furthermore, we extend some previous results to the countable state
space case. In addition, we consider optimization within the general set
of randomized policies, and not only within the restricted class of
Markovian deterministic policies. We model risk sensitivity as being
given by an exponential disutility function
U<sub>γ</sub>(x)=(sgnγ)e<sup>γx</sup>, where γ
is the constant risk-sensitivity coefficient. After basic definitions
and notation, the paper presents and briefly analyzes alternative
definitions of the exponential average cost criterion (EAC). Howard and
Matheson's definition of EAC (1972) is discussed in detail. Finally we
show that, similarly to the risk-neutral case, the optimal EAC satisfies
an optimality equation
Decision and Control, 1997., Proceedings of the 36th IEEE Conference on; 01/1998
[Show abstract][Hide abstract] ABSTRACT: To review the psychometric validation of the Chronic Venous dIsease quality of life Questionnaire (CIVIQ-20) in the countries that have used it since 1996.
Prospective, clinical, international study in 18 countries.
Patients with venous disease of the lower limb in the clinical, aetiological, anatomical and pathophysiological (CEAP) clinical stages C0s to C4 presenting to surgical outpatient departments and general practices and receiving drug treatment for 6 months.
Quantification of symptoms on a four-point scale and pain on a visual analogue scale, and self-administration of CIVIQ-20 to patients before visit (baseline, 2, 4 and 6 months).
In 3956 patients, CIVIQ-20 showed good internal consistency and reliability (above 0.80) through test-retest correlations. The discriminating power of items was good in known groups of patients. Factor analysis identified physical, psychological and pain factors as important, but revealed instability of the social factor. CIVIQ-20 was highly sensitive to changes in the quality of life of patients clinically improved after drug treatment.
CIVIQ-20 is valuable in assessing treatment effects in longitudinal, multinational studies, but comparisons of different populations should use the global score rather than scores per dimension.
European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery 09/2010; 40(6):783-9. DOI:10.1016/j.ejvs.2010.03.034 · 2.49 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: The aim of this large survey was to evaluate non-compliance with compression stockings in chronic venous disorder (CVD) patients.
A total of 16,770 CVD patients participated in this study.
Compression stockings were used by 25.6% of CVD patients and 46.6% of the patients were never prescribed compression therapy. Compression stocking use was found to increase with the clinical stage of CVD. The percentage of patients using compression stockings during control visits increased to 37.4%. Furthermore, 5.3% of the patients coming to control visits discontinued the use of compression stockings owing to high cost, sweating, itching, cosmetic reason, oedema exacerbation, exudation lesions of lower legs and application difficulty. Past episodes of vein thrombosis (OR = 0.80), of stroke (OR = 0.28) and of varicose veins surgery (OR = 0.28) were decreasing, while the management by a general practitioner was increasing the risk (OR = 1.36) of compression therapy cessation.
(1) Compression stockings are too rarely prescribed and often unaccepted at early stages of CVD; (2) The common reason for discontinuation of compression therapy is its high cost.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.